<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110768">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01669265</url>
  </required_header>
  <id_info>
    <org_study_id>SOLTI-1113</org_study_id>
    <nct_id>NCT01669265</nct_id>
  </id_info>
  <brief_title>Sentinel Lymph Node Total Tumoral Load as a Predictor of Non Sentinel Node Involvement in Early Breast Cancer</brief_title>
  <acronym>SOLO-1</acronym>
  <official_title>Sentinel Lymph Node Total Tumoral Load as a Predictor of Non Sentinel Node Involvement in Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOLTI Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sysmex America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SOLTI Breast Cancer Research Group</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective, multicentric cohort study of patient cases with cT1-3, N0 early
      breast cancer, who previously had intraoperative sentinel lymph node (SLN) evaluation by
      one-step nucleic acid amplification (OSNA) assay with a complete axillary dissection.

      The aim of the present study is to assess the intraoperative positive SLN total tumor load
      (TTL) obtained from the OSNA assay and to determine whether this TTL predicts non-SLN
      metastasis in patients with clinically node-negative early-stage breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Estimate the negative predictive value of the technique OSNA.</measure>
    <time_frame>At time of surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimate the negative predictive value of the technique OSNA for the cutoff point that maximizes (tentatively, 10,000 to 15,000 copies / uL) of axillary lymph node involvement in breast cancer early N0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ROC curve that describes the assay</measure>
    <time_frame>At time of surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>ROC curve (Receiver Operating Characteristic) from the true and false positives and negatives of OSNA test for different cutoffs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of the assay</measure>
    <time_frame>At time of surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Probability that OSNA in sentinel lymph nodes (SLN) is positive given that there is involvement of non-sentinel lymph nodes (NSLN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of the assay</measure>
    <time_frame>At time of surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Probability that OSNA in SLN is negative because there is no involvement of NSLN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likelihood ratio for the cutoff of 10,000-15,000 copies/uL</measure>
    <time_frame>At time of surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Likelihood ratio of positive and negative results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value at the cutoff of 10.000-15.000 copies/μL.</measure>
    <time_frame>At time of surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">701</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>OSNA</arm_group_label>
    <description>Patient cases with cT1-3, N0 early breast cancer, who previously had intraoperative sentinel lymph node (SLN) evaluation by one-step nucleic acid amplification (OSNA) assay with a complete axillary dissection.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cT1-3, N0 breast cancer, who had intraoperative SLN evaluation by OSNA assay
        with a complete axillary lymph node dissection.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed invasive breast carcinoma

          -  Stage T1-3,N0 evaluated by physical exam or imaging according to AJCC v.7 and best
             clinical local practices

          -  Intraoperative evaluation of sentinel lymph node (SLN) by OSNA

          -  Complete dissection of axillary lymph nodes after the evaluation of the SLNs by OSNA

          -  Pathology report of the tumor and dissected lymph nodes that includes the following
             information:

               -  primary tumor size (mm), tumor grade (Scarff-Bloom Richardson), estrogen
                  receptor status

               -  progesterone receptor status

               -  HER2 status (ASCO/CAP guidelines)

               -  Ki67 index

               -  presence/absence of lymphovascular invasion

               -  total number of sentinel and non-sentinel lymph nodes dissected during surgery

               -  total number of positive and negative sentinel and non-sentinel lymph nodes,
                  *size of the metastasis in both sentinel and non-sentinel lymph nodes

               -  total tumoral load in each sentinel lymph node, expressed as number of CK19 mRNA
                  copies per microliter.

        Exclusion Criteria:

          -  Patients who underwent neoadjuvant chemotherapy

          -  CK19-negative breast tumor

          -  ALND with &lt;10 lymph nodes

          -  In situ carcinoma only

          -  Metastatic breast cancer at time of diagnosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Peg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vall d´Hebron University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Rubio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vall d´Hebron University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Espinosa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vall d´Hebron University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vall d´Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago de Compostela</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Doctor Negrin</name>
      <address>
        <city>Las Palmas</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gruposolti.org</url>
    <description>SOLTI Breast Cancer Research Group</description>
  </link>
  <results_reference>
    <citation>Peg V, Espinosa-Bravo M, Vieites B, Vilardell F, Antúnez JJ, Salas MS, Sansano I, Delgado Sánchez JJ, Pinto W, Gozalbo F, Petit A, Rubio I. Intraoperative molecular analysis of sentinel lymph node as a new predictor of axillary status in early breast cancer. Poster session presented at: 35th Annual San Antonio Breast Cancer Symposium (SABCS); 2012 December 4th-8th; San Antonio, Texas, United States.</citation>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 10, 2012</lastchanged_date>
  <firstreceived_date>May 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>OSNA</keyword>
  <keyword>sentinel lymph node</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
